Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T19:40:47.400Z.
Calculation as of: 2026-10-06T19:40:47.400Z.
Quote observation: 2026-10-06T19:36:41.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5a667a199b47e7e336467208d2f6772290b800d1a0ab6507ee3a182ebbb9f075
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
BGM Group Ltd.
Market Cap
$118.12M
EV/EBITDA Ratio
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO |
|---|---|---|
| BGM Group Ltd. (BGM) | $118.12M | N/A |
| LENZ Therapeutics, Inc. (LENZ)vs › | $118.99M | N/A |
| Spruce Biosciences, Inc. (SPRB)vs › | $118.77M | N/A |
| Tenaya Therapeutics, Inc. (TNYA)vs › | $119.41M | N/A |
| Cibus, Inc. (CBUS)vs › | $121.37M | N/A |
| Seer, Inc. (SEER)vs › | $120.68M | N/A |
| enGene Holdings Inc. (ENGN)vs › | $121.25M | N/A |
| Lucid Diagnostics Inc. (LUCD)vs › | $114.56M | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $114.47M | N/A |
| MaxCyte, Inc. (MXCT)vs › | $114.08M | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
